Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.

Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.

Abstract: Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated with those diseases.

Abstract: Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated with those diseases.

Abstract: Methods of treating a host suffering from restenosis are provided. The methods include delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The methods further include the administration of a chemotherapeutic agent in combination with delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The chemotherapeutic agent may be coated on the stent or administered systemically.

Abstract: Methods of treating a host suffering from obesity or an overweight condition are provided. Methods of preventing obesity or an overweight condition are also provided. The methods include delivery of a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist, or hypoestes dried leaf powder to a host suffering from obesity or an overweight condition or a host at risk for developing obesity or becoming overweight. The methods further include the administration of a chemotherapeutic agent, such as a non-steroidal anti-inflammatory drug, in combination with delivery of a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist, or hypoestes dried leaf powder.

Abstract: Methods of alleviating skin conditions are provided. The methods comprise application to a host's skin of an effective amount, in a cosmetic composition or in isolation, of hypoestoxide crude extract, hypoestes rosea dried leaf powder or a hypoestoxide, derivative or agonist thereof, such that the skin irritation or condition is improved or alleviated. The methods further include application of the hypoestoxide compounds in combination with salicylic acid derivatives, hydroxy acids, retinol and its esters, retinoic acid and its derivatives, perfumes, fragrances, aftershaves, deodorants and with vitamins.

Abstract: Methods of treating a host suffering from restenosis are provided. The methods include delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The methods further include the administration of a chemotherapeutic agent in combination with delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The chemotherapeutic agent may be coated on the stent or administered systemically.

Abstract: Methods for treatment and prophylaxis of hyperlipidemias, including hypertriglyceridemia and hypercholesterolemia, are provided. The methods include administering to a host a therapeutically or prophylactically effective amount of a diterpene compound, such as a hypoestoxide.

Abstract: Novel enhanced usage of hypoestoxides derivatives and agonists theeof as active agents against nucleated infectious entities including known parasites and the like microbiological insultors of living tissue, systems and organisms, known modes of administration and related compounds are used alone or in combination with the instant teachings.

Abstract: A method for inhibiting the growth of lentiviruses and Herpetoviridae viruses, including HIV-1 and HSV-1, -2, respectively, in subjects, comprising administering to a subject in need of antiviral therapy a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula ##STR1## where: R is(i) H, PO.sub.3.sup..dbd., alkyl of 1 to 12 carbon atoms substituted or unsubstituted, straight chain or branched, 0 to 6 double bonds, (CH.sub.2).sub.n morpholine where n=1-4, morpholinomethylphenyl, orthoaminophenyl, orthohydroxyphenyl, (CH.sub.2).sub.n COOR.sub.2 where n=1-4where R.sub.2 is H, an alkalai metal salt, an alkaline earth metal salt, NH.sub.4.sup..dbd., N.sup.+ (R.sub.3).sub.4where R.sub.3 is independently selected from the group consisting of H and alkyl of 1 to 4 carbon atoms, or(ii) COR.sub.1 wherein R.sub.1 is selected from the group consisting of H, (CH.sub.2).sub.n CH.sub.3, where n=0-6, (CH.sub.2).sub.n COOR.sub.2 where n=1-4 and R.sub.2 is previously defined, (CH.

Abstract: A method for inhibiting the growth of cancer cells ous tumors. The method comprises administering to a subject in need of anticancer or antitumor therapy a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula ##STR1## where: R is(i) H, PO.sub.3.sup..dbd., alkyl of 1 to 12 carbon atoms substituted or unsubstituted, straight chain or branched, 0 to 6 double bonds, (CH.sub.2).sub.n morpholine where n=1-4, morpholinomethylphenyl, orthoaminophenyl, orthohydroxyphenyl, (CH.sub.2).sub.n COOR.sub.2 where n=1-4where R.sub.2 is H, an alkali metal salt, an alkaline earth metal salt, NH.sub.4.sup.+, N.sup.+ (R.sub.3).sub.4 where R.sub.3 is independently selected from the group consisting of H and alkyl of 1 to 4 carbon atoms, or(ii) COR.sub.1 wherein R.sub.1 is selected from the group consisting of H, (CH.sub.2).sub.n CH.sub.3, where n=0-6, (CH.sub.2).sub.n COOR.sub.2 where n=1-4 and R.sub.2 is previously defined, (CH.sub.2).sub.n N.sup.+ (R.sub.3).sub.

Abstract: Methods for inducing immunosuppression in animals which need immunosuppressive treatment involving administration to animals of a therapeutically effective amount of the cyclic AMP agent HE-33 or its nucleoside.

Abstract: Methods and compounds for inducing immunosuppression in animals which need immunosuppressive treatment involving administration to animals of a therapeutically effective amount of a compound of the following formula ##STR1## where R is H, PO.sub.3.sup.=, alkyl of 1 to 12 carbon atoms substituted or unsubstituted, straight chain or branched, 0 to 6 double bonds, (CH.sub.2).sub.n morpholine where n=1-4, morpholinomethylphenyl, orthoaminophenyl, orthohydroxyphenyl, (CH.sub.2).sub.n COOR.sub.2 where n=1-4where R.sub.2 is H, an alkalai metal salt, an alkaline earth metal salt, NH.sub.4.sup.+, N.sup.+ (R.sub.3).sub.4 where R.sub.3 is independently selected from the group consisting of H and alkyl of 1 to 4 carbon atoms,COR.sub.1 wherein R.sub.1 is selected from the group consisting of H, (CH.sub.2).sub.n CH.sub.3, where n=1-6, (CH.sub.2).sub.n COOR.sub.2 where n=1-4 and R.sub.2 is previously defined, (CH.sub.2).sub.n N.sup.+ (R.sub.3).sub.4 wherein n=1-4, and (CH.sub.2).sub.n SO.sub.3.sup.

Abstract: An in vitro method for diagnosing hypersensitivity to silicon(e) antigen in subjects not previously exposed to silicon(e). The method involves obtaining a subset of lymphocytes from non-sensitized subjects and contacting the lymphocytes with silicon(e) for a sufficient period of time to cause sensitizing and proliferative responses.

Abstract: Methods for inducing immunosuppression in animals which need immunosuppressive treatment involving administration to animals of a therapeutically effective amount of the cyclic AMP agent HE-33 or its nucleoside.